Zekai Tahir Burak Maternity and Teaching Hospital, Neonatal Intensive Care Unit, 06111 Ankara, Turkey.
Ann Clin Biochem. 2011 Sep;48(Pt 5):462-7. doi: 10.1258/acb.2011.010285. Epub 2011 Jul 20.
Oxidative damage is important in the pathogenesis of respiratory distress syndrome (RDS). However, data on the effect of surfactant therapy on oxidative stress in vivo are limited. We aimed to evaluate the oxidant/antioxidant status in preterm infants with RDS via measurement of total antioxidant capacity (TAC) and total oxidant status (TOS), to determine the effect of surfactant on oxidant/antioxidant balance and to assess the association between TAC, TOS and clinical outcomes of the patients.
Sixty-nine infants with RDS were included. Blood samples for determining TAC and TOS were collected before and 48 h after surfactant treatment. TAC and TOS levels were analysed in serum. Patients were followed up until discharge or death.
Post-surfactant TAC levels were significantly higher than pre-surfactant TAC levels (P = 0.029). TAC/TOS ratio significantly increased after surfactant treatment (P = 0.018). Infants <28 weeks of gestational age had lower levels of baseline TAC than those ≥28 weeks of gestational age (P = 0.020), whereas TOS levels were similar. Baseline TAC/TOS ratio was lower in infants who died in the study period than those who survived (P = 0.023). After controlling gestational age, baseline TAC levels were significantly and inversely correlated with the duration of total respiratory support (r = -0.343; P = 0.009) and hospitalization (r = -0.341; P = 0.009). TAC or TOS levels were not associated with the development of bronchopulmonary dysplasia or other complications as determined during the investigation period.
Oxidant-antioxidant balance shifts in favour of the antioxidant system after surfactant treatment. Lower TAC/TOS ratio in preterm infants may be associated with increased mortality.
氧化损伤在呼吸窘迫综合征(RDS)的发病机制中很重要。然而,关于表面活性剂治疗对体内氧化应激影响的数据有限。我们旨在通过测量总抗氧化能力(TAC)和总氧化状态(TOS)来评估 RDS 早产儿的氧化剂/抗氧化剂状态,确定表面活性剂对氧化剂/抗氧化剂平衡的影响,并评估 TAC、TOS 与患者临床结局之间的关系。
纳入 69 例 RDS 婴儿。在表面活性剂治疗前和治疗后 48 小时采集血液样本以测定 TAC 和 TOS。分析血清中的 TAC 和 TOS 水平。患者随访至出院或死亡。
表面活性剂治疗后 TAC 水平明显高于治疗前(P=0.029)。表面活性剂治疗后 TAC/TOS 比值显著升高(P=0.018)。胎龄<28 周的婴儿基础 TAC 水平低于胎龄≥28 周的婴儿(P=0.020),而 TOS 水平相似。研究期间死亡的婴儿基础 TAC/TOS 比值低于存活的婴儿(P=0.023)。在控制胎龄后,基础 TAC 水平与总呼吸支持时间(r=-0.343;P=0.009)和住院时间(r=-0.341;P=0.009)呈显著负相关。TAC 或 TOS 水平与调查期间发生支气管肺发育不良或其他并发症无关。
表面活性剂治疗后,氧化还原平衡向抗氧化系统倾斜。早产儿 TAC/TOS 比值较低可能与死亡率增加有关。